PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Related documents

• Identification and characterisation of novel ligands presented by major histocompatibility complex class I-related protein 1(MR1)#637788
• CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms#1032066
• Machine learning-based prediction and external validation of treatment-related myelosuppression in patients with non-small cell lung cancer receiving PD-1 inhibitors plus platinum-doublet chemotherapy.#685575
• Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC#201595
• M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability#1152775